IGC Pharma Inc Stock Price, News & Analysis

IGC Pharma (NYSE American: IGC) announced that Alliance Global Partners published an updated equity research report on February 10, 2026. The report reiterates a Buy rating and sets a $3.00 price target per share. IGC disclaims endorsement and does not guarantee the report's accuracy.

IGC Pharma (NYSE:IGC) expanded its Phase 2 CALMA trial for IGC-AD1 into Colombia by adding Grupo de Neurociencias de Antioquia (GNA), increasing the clinical network to 23 active sites across 26 locations in the US and Canada plus Colombia. CALMA has reached approximately 70% of planned enrollment with completion expected by mid-2026, the operational gating step before database lock and topline results. GNA brings longitudinal cohorts and biomarker expertise; Dr. Claudia Ramos will serve as Principal Investigator, supported by GNA leadership and multidisciplinary teams.

IGC Pharma (NYSE:IGC) reported reaching approximately 70% enrollment in its Phase 2 CALMA trial of IGC-AD1 for agitation associated with Alzheimer’s disease. The company has about 23 active sites across 26 locations and expects to complete enrollment by mid-2026, moving toward database lock and topline results.

IGC said enrollment uses a hybrid decentralized model to expand patient access; efficacy outcomes are not analyzed ongoing to preserve blinding and trial integrity.

IGC Pharma (NYSE American: IGC) announced on January 22, 2026 that Integrative Clinical Trials, LLC in Brooklyn, New York, has joined its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.

The new site, led by Principal Investigator Dr. Inna Yuryev-Golger, MD, expands the trial's clinical footprint in a major metropolitan area and is expected to support patient enrollment and diversity given the site's CNS research experience. IGC-AD1 is being studied in a randomized, double-blind, placebo-controlled Phase 2 trial. The company said the site addition strengthens trial execution and data quality as CALMA advances.

IGC Pharma (NYSE:IGC) added Dominion Medical Associates, a Lightship network site in Richmond, Virginia, to its Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer's disease on January 12, 2026. The site will use Lightship's hybrid access model combining in-clinic, remote, and in-home visits supported by mobile research nurses and validated technology to expand access, reduce participant burden, improve retention, and accelerate enrollment across underserved and rural communities. IGC-AD1 is a cannabinoid-based investigational therapy being studied in a randomized, double-blind, placebo-controlled Phase 2 trial. The expansion aims to strengthen trial execution, participant diversity, and timely study completion while maintaining investigator oversight, protocol adherence, and data integrity.

IGC Pharma (NYSE American: IGC) announced on January 6, 2026 that its Board approved changing the company fiscal year end from March 31 to December 31, effective December 31, 2025. The company said the alignment with the calendar year is intended to improve clarity, comparability, and accessibility of financial reporting for U.S. investors and to support more consistent communication with U.S. capital markets as clinical and AI programs advance.

As a result, IGC Pharma will file a transition Form 10-K covering the nine-month period from April 1, 2025 through December 31, 2025, and will report on a calendar-year basis beginning in 2026. The company does not expect the change to affect business operations, strategic priorities, or SEC compliance.

IGC Pharma (NYSE American: IGC) announced a registered direct offering of 779,997 shares at $0.30 per share, expected to raise approximately $234,000 in gross proceeds on January 5, 2026. The company said net proceeds will be used for working capital and general corporate purposes, including continued funding of its IGC-AD1 Phase 2 clinical development program for Alzheimer’s disease.

The shares were offered under an effective shelf registration on Form S-3 (File No. 333-276330) declared effective January 8, 2024. Management described the new investors as long-term, strategic supporters who may provide experience and networks to advance IGC’s clinical programs.

IGC Pharma (NYSE American: IGC) announced that the USPTO issued U.S. Patent No. 12,491,200 on December 19, 2025, covering a novel microdose-based cannabinoid treatment for stuttering and Tourette's Syndrome.

The patent protects ultra-low THC dosing, alone or with CBD or other agents, to modulate neural circuits tied to vocal disruptions and tics, and complements IGC's existing neurological pipeline including IGC-AD1 in the CALMA trial for agitation in Alzheimer's disease.

IGC Pharma (NYSE American: IGC) commented on recent federal momentum toward possible Schedule III reclassification for cannabinoids and positioned itself as a focused beneficiary within the FDA-regulated pharmaceutical pathway. The company highlighted its lead candidate, IGC-AD1, currently in a Phase 2 CALMA study for agitation associated with Alzheimer’s disease, and emphasized a long‑horizon strategy built on microdosing, safety, patents, and AI-driven drug development.

IGC outlined potential long-term benefits if policy evolves, including expanded clinical institution participation, more efficient pharma-grade manufacturing and supply chains, and improved engagement from financial institutions and capital markets.